| 6777- | EGCG, | Health Benefits and Chemical Composition of Matcha Green Tea: A Review |
| - | Review, | Nor, | NA |
| 6783- | EGCG, | Absorption, metabolism, bioactivity, and biotransformation of epigallocatechin gallate |
| - | Review, | Nor, | NA |
| 6782- | EGCG, | Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability |
| - | Human, | Nor, | NA |
| 6789- | EGCG, | Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? |
| - | Review, | Var, | NA |
| 6788- | EGCG, | A systematic review and meta-analysis of the effects of green tea extracts and polyphenols in female hormone-dependent cancers for benefit-risk evaluation |
| - | Review, | BC, | NA | - | Review, | Ovarian, | NA |
| 6787- | EGCG, | statins, | An Update on Impacts of Epigallocatechin Gallate Co-administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers |
| - | Review, | Nor, | NA |
| 6786- | EGCG, | Chemoprophylaxis Effect of EGCG on the Recurrence of Colorectal Cancer: A Systematic Review and Meta-Analysis |
| - | Study, | CRC, | NA |
| 6785- | EGCG, | Epigallocatechin-3-gallate at the nanoscale: a new strategy for cancer treatment |
| - | Review, | Var, | NA |
| 6784- | EGCG, | Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications in Nutrition and Health |
| - | Review, | Nor, | NA |
| 6410- | EGCG, | Evaluation of the neuroprotective effect of EGCG: a potential mechanism of mitochondrial dysfunction and mitochondrial dynamics after subarachnoid hemorrhage |
| - | in-vitro, | Nor, | NA |
| 6411- | EGCG, | Pharmacological and Genetic Approaches to Downregulate FIS1 Mitigate Neuropathic Pain |
| - | in-vivo, | Nor, | NA |
| 2310- | EGCG, | Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells |
| - | in-vitro, | lymphoma, | PEL |
| 2395- | EGCG, | EGCG inhibits diabetic nephrophathy through up regulation of PKM2 |
| - | Study, | Diabetic, | NA |
| 2302- | EGCG, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2309- | EGCG, | Chemo, | Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Nor, | HPNE | - | in-vitro, | PC, | PANC1 | - | in-vivo, | NA, | NA |
| 2994- | EGCG, | Nano-Engineered Epigallocatechin Gallate (EGCG) Delivery Systems: Overcoming Bioavailability Barriers to Unlock Clinical Potential in Cancer Therapy |
| - | Review, | Var, | NA |
| 2993- | EGCG, | Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP |
| 2992- | EGCG, | Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity |
| - | Review, | Var, | NA |
| 2561- | EGCG, | ASA, | Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment |
| - | ex-vivo, | Nor, | NA |
| - | Trial, | Nor, | NA |
| 2563- | EGCG, | Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies |
| - | Review, | Stroke, | NA |
| 2501- | EGCG, | A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea |
| - | Case Report, | AML, | NA |
| 2468- | EGCG, | Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists |
| - | in-vitro, | Nor, | NA |
| 2458- | EGCG, | QC, | Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies |
| - | Analysis, | Nor, | NA |
| 2459- | EGCG, | Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis |
| - | in-vitro, | Tong, | Tca8113 | - | in-vitro, | Tong, | TSCCa |
| - | in-vitro, | Nor, | HSC-T6 |
| 4680- | EGCG, | The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review |
| - | Review, | Var, | NA |
| 4684- | EGCG, | EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells |
| - | in-vivo, | NSCLC, | A549 |
| 4681- | EGCG, | Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling |
| - | in-vitro, | Ovarian, | ES-2 |
| 4682- | EGCG, | Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate |
| - | Review, | Var, | NA |
| 4683- | EGCG, | Epigallocatechin-3-gallate inhibits self-renewal ability of lung cancer stem-like cells through inhibition of CLOCK |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vivo, | Lung, | A549 |
| 4685- | EGCG, | Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines |
| - | in-vitro, | NPC, | TW01 | - | in-vitro, | NPC, | TW06 |
| 4291- | EGCG, | Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro |
| - | in-vitro, | AD, | NA |
| 4290- | EGCG, | EGCG impedes human Tau aggregation and interacts with Tau |
| - | in-vitro, | AD, | NA |
| - | in-vitro, | GBM, | U87MG |
| 1975- | EGCG, | Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate |
| - | in-vitro, | Cerv, | HeLa |
| 1974- | EGCG, | Protective Effect of Epigallocatechin-3-Gallate in Hydrogen Peroxide-Induced Oxidative Damage in Chicken Lymphocytes |
| - | in-vitro, | Nor, | NA |
| 1514- | EGCG, | Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 |
| 1503- | EGCG, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 1516- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | Var, | NA |
| 1515- | EGCG, | Phen, | Reciprocal Relationship Between Cytosolic NADH and ENOX2 Inhibition Triggers Sphingolipid-Induced Apoptosis in HeLa Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | BT20 |
| 1303- | EGCG, | (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation |
| - | in-vitro, | EC, | NA |
| 26- | EGCG, | QC, | docx, | Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy |
| - | vitro+vivo, | Pca, | PC3 |
| 20- | EGCG, | Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer |
| - | in-vivo, | Liver, | NA | - | in-vivo, | Tong, | NA |
| 21- | EGCG, | Tea polyphenols EGCG and TF restrict tongue and liver carcinogenesis simultaneously induced by N-nitrosodiethylamine in mice |
| - | in-vivo, | Liver, | NA |
| 22- | EGCG, | Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics |
| - | in-vitro, | PC, | CD133+ | - | in-vitro, | PC, | CD44+ | - | in-vitro, | PC, | CD24+ | - | in-vitro, | PC, | ESA+ |
| 23- | EGCG, | (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells |
| - | in-vitro, | Chon, | SW1353 | - | in-vitro, | Chon, | CRL-7891 |
| 24- | EGCG, | GEN, | QC, | Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin |
| - | in-vitro, | Pca, | 22Rv1 |
| 25- | EGCG, | QC, | Quercetin Increased the Antiproliferative Activity of Green Tea Polyphenol (-)-Epigallocatechin Gallate in Prostate Cancer Cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 1036- | EGCG, | Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | LU99 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid